A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

← catalyst calendar

NCT05980806 · readout ≤ 315 d

Sponsored by Karyopharm Therapeutics Inc (industry) · KPTI — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

58estimated

Sites

Countries

Belgium, Bulgaria, Canada +16

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-04-22

actual

When the study began enrolling

Primary completion

Jun 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Oct 2028

estimated

The whole study's end, after follow-up

First posted

2023-08-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-02-12

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Myelofibrosis
Moderate Thrombocytopenia
Mild Thrombocytopenia

Interventions

Drug: Selinexor 60 mg — also filed as KPT-330
Drug: Selinexor 40 mg — also filed as KPT-330
Drug: Ruxolitinib — also filed as JAKAFI
Drug: Pacritinib — also filed as VONJO
Drug: Momelotinib — also filed as OJJAARA

Primary outcome

what the primary-completion date above is the date OF

Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24

measured At Week 24

Permalink · KPTI's whole pipeline · Catalyst calendar · Every registered study · What changed